HLA-A and cancer: Interactions for activating KIRs (aKIR) have been reported for KIR2DS1/HLA-C2 [28,29], KIR2DS2/C1 [30], KIR2DS2/HLA-A*11 [31], KIR2DS2/non-HLA ligands expressed in cancer [32], KIR2DS4/HLA-A*11, C*01:02, C*02:02, C*04:01, C*05:01, C*14:02, and C*16:01 [33].